WM facts Flashcards
Median age WM
71
M:F WM
3:1
anti-MAG IgM clinical syndrome
chronic demyelinating neuropathy
Monotherapy with R
50% ORR
MYD88 in WM
L265P
93%
not diagnostic (seen in 5% of MZL)
not clear if prognostic
concordant with the extent of BM involvement
CXCR4 mutations in WM
30%
but 50% of pts with hyperviscosity
shorter treatment free survival
Ibrutinib resistance
risk factors for IgM MGUS advancement to WM
abnormal kappa/lambda ratio
M protein > 1.5
MYD88 mutation
Symptomatic hyperviscosity in WM %
13%
Risk factors in WM to require Tx
IgM > 4500 mg%
BM involvement > 70%
B2MG > 4
Alb< 3.5
S/Sx of hyperviscosity syndrome
epistaxis
gingival bleeding
retinal hemorrhage
Tx of hyperviscosity syndrome
plasma exchange
usually once is enough
Cutoff of hyperviscosity syndrome
IgM > 4
Rituximab risk in WM
flare of hyperviscosity
1st lIne Tx of WM
BR
R(rituximab)-Vd
R-K
Main R Tx in WM
no benefit
Tx of IgM nephropathy in WM
R monotherapy